Autopsy report · NCT06922604

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

“Pending Amendment Approval”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Suspended: paused, and may or may not restart.
• 20 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

City of Hope Medical Center

Sponsor type

University, hospital or other

Conditions

Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma

Interventions

Biospecimen Collection; Computed Tomography; Glofitamab; Lumbar Puncture; Magnetic Resonance Imaging; Obinutuzumab

Participants

20 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75
  “The inclusions have been suspended pending approval of an amendment to the protocol” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.